News
ORYZF
3.450
NaN%
--
Oryzon Genomics: Advancing LSD1 Pipeline and Strong Cash Position Support Unchanged $10 Price Target and Buy Rating
TipRanks · 07/30 00:15
Oryzon Genomics Restates 2025 Interim Results After Accounting Policy Change
TipRanks · 07/28 14:23
Roth MKM Sticks to Their Buy Rating for Oryzon Genomics SA (ORN)
TipRanks · 07/28 13:46
Oryzon Genomics Updates Loyalty Share Voting Rights Structure
TipRanks · 07/22 13:23
Oryzon Genomics Completes €12 Million Share Capital Increase
TipRanks · 07/07 12:03
Oryzon Genomics Raises €12 Million Through Discounted Private Share Placement
TipRanks · 07/02 11:16
Oryzon Genomics Shareholders Approve All Resolutions at 2026 General Meeting
TipRanks · 07/02 11:13
Oryzon Genomics launches capital raise and secures €25m anchor commitment for R&D
TipRanks · 07/01 11:21
Buy Rating Reiterated on Oryzon as Advancing AML Franchise and Strong Iadademstat Data Support Unchanged $10 Price Target
TipRanks · 06/12 16:55
Oryzon Updates Loyalty Share Double Voting Rights and Total Votes
TipRanks · 06/09 14:54
Jefferies Remains a Buy on Oryzon Genomics SA (ORN)
TipRanks · 05/25 12:46
Buy Rating Reaffirmed on Oryzon as Iadademstat Delivers Strong Early AML Responses and Approaches Key Pivotal Catalyst Milestones
TipRanks · 05/16 14:55
Oryzon Genomics announces patent grant decision in Mexico
TipRanks · 03/12 12:10
Oryzon Genomics receives EMA approval for Phase II study of iadademstat
TipRanks · 02/24 13:24
Oryzon Genomics appoints Rolando Gutierrez-Esteinou as CMO, CNS Programs
TipRanks · 02/12 13:21
Oryzon Genomics management to meet with Maxim
TipRanks · 02/11 16:45
Oryzon Genomics announces first patient dosed in Phase Ib iadademstat study
TipRanks · 02/09 13:05
Oryzon Genomics receives Decision to Grant from Japanese Patent Office
TipRanks · 02/02 13:16
Oryzon Genomics receives Decision to Grant from Japanese Patent Office
TipRanks · 12/22/2025 13:15
Oryzon Genomics announces results of Extraordinary General Shareholders’ meeting
TipRanks · 12/15/2025 13:55
More
Webull provides a variety of real-time ORYZF stock news. You can receive the latest news about Oryzon Genomics through multiple platforms. This information may help you make smarter investment decisions.
About ORYZF
Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The Company also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.